IFNG and myeloid sarcoma: In contrast to an earlier study, the current research broadens the monitoring to a comprehensive array of immune markers using QFM, followed by an extensive evaluation of selected inflammatory markers through Luminex technology (IFN-α, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, IL-15, IL-33, VEGF), and substantiating these promising indicators with the ELISA technique (IL-1α, IL-1ra, IL-6, VEGF), thus offering an expansive overview of the immune landscape in MS.